Biosimilars in Oncology
Bioequivalence assessment is a crucial step in the evaluation of generic drugs or biosimilar products. It compares the pharmacokinetic and sometimes pharmacodynamic properties of a generic/biosimilar drug to that of a reference drug (innovator drug) to determine if they are equivalent in terms of safety and efficacy.
The purpose of bioequivalence assessment is to demonstrate that the generic or biosimilar product is highly similar to the reference product, showing comparable bioavailability and similar therapeutic effects. It is based on the principle that if two products are bioequivalent, they can be expected to have the same therapeutic outcome when administered to patients at the same dosage